

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1-52. (canceled)

53. (currently amended) A ~~sustained release oral dosage form comprising:~~

a liquid antiviral drug composition consisting of an antiviral drug solubilized in a polysorbate surfactant.

54. (canceled)

55. (currently amended) The ~~sustained release dosage form~~ composition of claim 53, wherein the antiviral drug is present in the liquid antiviral drug composition in an amount of approximately 5 wt% to 60 wt% and the ~~solvent polysorbate surfactant~~ is present in an amount of approximately 20 wt% to 95 wt%.

56. (canceled)

57. (canceled)

58. (currently amended) The ~~sustained release dosage form~~ composition of claim 53, wherein the antiviral drug is a protease inhibitor.

59. (currently amended) The sustained release dosage form of claim ~~[[53]]~~ 75, which can produce an average steady-state plasma concentration of the antiviral drug greater than a therapeutically effective concentration of the antiviral drug over a period of about 4 hours to about 24 hours.

60. (currently amended) The ~~sustained release dosage form~~ composition of claim 53, for use in treating a condition in a subject responsive to the antiviral drug, wherein said condition is acquired immune deficiency syndrome (AIDS) associated with human immunodeficiency virus (HIV) infection in the subject.

61. (currently amended) The sustained release dosage form of claim [[53]] 75, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 4 hours after administration with no more than 30% by weight of the antiviral drug composition being released within the first 1 hour after oral administration.

62. (currently amended) The sustained release dosage form of claim [[53]] 75, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 12 hours after administration with no more than 30% by weight of the antiviral drug composition being released within the first 4 hours after oral administration.

63. (currently amended) The sustained release dosage form of claim [[53]] 75, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 24 hours after administration with no more than 30% by weight of the antiviral drug composition being released within the first 12 hours after oral administration.

64. (currently amended) The sustained release oral dosage form of claim [[53]] 75, ~~further comprising~~ consisting of:

- a wall defining a compartment, the wall comprising a semipermeable layer;
- an expandable layer located within the compartment and in fluid communication with the semipermeable layer;
- a capsule located within the compartment and in direct or indirect contacting relationship with the expandable layer, the capsule containing the liquid antiviral drug composition; and
- an exit orifice formed or formable in the dosage form extending from the external surface of the capsule to an environment of use.

65. (original) The sustained release dosage form of claim 64, wherein the expandable layer is located within the capsule and is remote from the exit orifice.

66. (original) The sustained release dosage form of claim 65, further comprising a barrier layer located within the capsule between the liquid antiviral drug composition and the expandable layer.

67. (original) The sustained release dosage form of claim 64, wherein the expandable layer is located within the compartment between the capsule and the semipermeable layer.

68. (original) The sustained release dosage form of claim 67, further comprising a barrier layer located within the compartment between the capsule and the expandable layer.

69. (original) The sustained release dosage form of claim 64, wherein the semipermeable layer comprises a semipermeable polymer and the expandable layer comprises a hydrophilic polymer.

70. (original) The sustained release dosage form of claim 69, wherein the expandable layer further comprises a lubricant and/or an osmotically effective compound.

71. (original) The sustained release dosage form of claim 70, wherein the hydrophilic polymer is present in an amount of up to 95 wt%, the osmotically effective compound is present in an amount of 0 wt% to 60 wt%, and the lubricant is present in an amount of 0 wt% to 5 wt% of the total composition of the expandable layer.

72. (original) The sustained release dosage form of claim 64, wherein the capsule is a gelatin capsule.

73. (currently amended) The ~~sustained release dosage form~~ composition of claim 53, wherein the polysorbate surfactant is selected from the group consisting of polyoxyethylene 20 sorbitan

monolaurate, polyoxyethylene 40 sorbitan monopalmitate, polyoxyethylene 60 sorbitan monostearate, and polyoxyethylene 80 sorbitan monooleate.

74. (currently amended) The ~~sustained release dosage form~~ composition of claim 58, wherein the protease inhibitor is selected from the group consisting of saquinavir, adefovir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine, and zalcitabin.

75. (new) The composition of claim 53 which is contained within a sustained release dosage form.